Abstract: Marek's disease virus (MDV), the etiologic agent of Marek's disease, is a potent oncogenic herpesvirus. MDV is highly contagious and elicits a rapid onset of malignant T-cell lymphomas in chickens within weeks after infection. MDV codes for an oncoprotein, Meq, that shares resemblance with the Jun/Fos family of b-ZIP transcription factors. Earlier studies showed that Meq is responsible for development for T-cell lymphomas in chicken. In order to identify specific regions within the Meq gene, a series of recombinant MDV were generated in which a mutated gene was introduced in place of parental Meq gene. Various mutations were introduced at the phosphorylation sites, basic region, leucine zipper region and transactivation regions of the Meq gene. Several of these mutations have been shown to have an attenuated phenotype in chickens. In one embodiment, the present invention contemplates exploiting these mutations to develop MDV vaccines that are able to protect against challenge with highly virulent MDV strains.

Abstract: Marek's disease virus (MDV), the etiologic agent of Marek's disease, is a potent oncogenic herpesvirus. MDV is highly contagious and elicits a rapid onset of malignant T-cell lymphomas in chickens within weeks after infection. MDV codes for an oncoprotein, Meq, that shares resemblance with the Jun/Fos family of b-ZIP transcription factors. Earlier studies showed that Meq is responsible for development for T-cell lymphomas in chicken. In order to identify specific regions within the Meq gene, a series of recombinant MDV were generated in which a mutated gene was introduced in place of parental Meq gene. Various mutations were introduced at the phosphorylation sites, basic region, leucine zipper region and transactivation regions of the Meq gene. Several of these mutations have been shown to have an attenuated phenotype in chickens. In one embodiment, the present invention contemplates exploiting these mutations to develop MDV vaccines that are able to protect against challenge with highly virulent MDV strains.

Abstract: A subsea connector is disclosed. The connector includes a guide funnel assembly that may be coupled to a subsea structure. The guide funnel assembly may receive a shaft. The shaft may be coupled to a bend restrictor/limiter or a bend stiffener. The shaft may be received inside the guide funnel assembly. The shaft may include a recess. A latch assembly may be coupled to the guide funnel assembly. The latch assembly may include one or more dogs and a latch operating device. The dogs may be radially moveable in and out of the interior of the guide funnel assembly. The dogs may be inserted into the recess of the shaft to inhibit longitudinal axial movement between the shaft and the guide funnel assembly. The latch operating device may control the in and out radial movement of the dogs.

Abstract: A subsea insulation device is described. The device includes a frame coupled to and at least partially enclosing a subsea component. A bag may be at least partially enclosed in the frame. The bag may substantially seal against at least one surface of the subsea component when the bag is at least partially inflated. A port may be attached to the bag. The port may allow the bag to be coupled to a fluid provider connector so that fluid can be provided into the bag to inflate the bag.

Abstract: An effective vaccine for Marek's disease may be prepared using a recombinant Marek's disease virus CVI988 transformed with a foreign DNA construct which includes a long terminal repeat sequence of a reticuloendotheliosis virus. This viral agent is effective to elicit an immune response in a chicken to Marek's disease virus without causing a significant degree of pathogenicity in the inoculated bird. Suitable formulations of the vaccine for use in chickens include an effective immunization dosage of this novel viral agent with a pharmaceutically acceptable carrier or diluent.